- Prevention Available to Combat Spread of Viruses
LAS VEGAS, April 28 /CNW/ -- Skinvisible, Inc. (OTC Bulletin Board:
SKVI), a research and development company of patented skincare and medical
dermatology products, has developed a hand sanitizing lotion that has proven
effective in killing the H1N1 swine flu virus found in pigs. Retroscreen
Virology of London England conducted the studies with Skinvisible's Hand
Sanitizer Lotion; DermSafe. The product demonstrated it had a greater than
99.99 % inactivation/kill on H1N1 influenza A, a virus similar to the human
swine flu virus.
The World Health Organization (WHO) yesterday raised the pandemic threat
to a phase 4 - "sustained human to human transmission". The Center for Disease
Control states that the virus spreads the same way the regular flu does; "Flu
viruses are spread mainly from person to person through coughing or sneezing
of people with influenza. Sometimes people may become infected by touching
something with flu viruses on it and then touching their mouth or nose."
When the lotion is applied to the hands, DermSafe is proven to not only
kill bacteria and viruses immediately but also to stay bound to the skin for 4
hours or more; continuing to kill germs - even after hand washing. The
product does not contain alcohol and therefore is non-drying and does not
present some of the dermatitis issues that alcohol-based products do.
"Skinvisible has a series of studies demonstrating that our DermSafe hand
sanitizer kills a host of viruses and bacteria, including several influenza
viruses such as H1N1 ('swine flu'), H3N2 and H5N1 ('avian bird flu virus'),"
said Mr. Terry Howlett, President and CEO of Skinvisible. "We are confident
that DermSafe can offer protection for people concerned about spreading germs
from person to person and we will continue to undertake more studies on these
and other viruses."
The active ingredient in DermSafe is chlorhexidine, which has been used
in hospitals worldwide for over fifty years as a pre-surgical hand scrub.
DermSafe is available for licensing both commercially in healthcare and food
services as well as for personal use (retail) worldwide. DermSafe has been
approved for distribution by Health Canada and the company is implementing a
plan to seek FDA approval in the US and worldwide.
Invisicare is Skinvisible's patented polymer delivery system that offers
life-cycle management and unique enhancements for topically delivered
products. It is a combination of hydrophilic and hydrophobic polymers that
hold active ingredients on the skin for extended periods of time resisting
both wash off and perspiration. Invisicare can control the release of
actives, reduce irritation and can eliminate some costly manufacturing
processes. It is non-occlusive and allows for normal skin respiration while
protecting against environmental irritants. www.invisicare.com
About Skinvisible Pharmaceuticals, Inc
Skinvisible Pharmaceuticals is a research-and-development company whose
primary business objective is to license its proprietary formulations with
Invisicare to pharmaceutical and cosmeceutical companies as well as assisting
companies in enhancing their existing skin care products. Skinvisible receives
a combination of research and development fees, upfront license fees, and
ongoing royalties for the life of the Invisicare patent. Skinvisible's value
also lies in its ability to continually generate new IP on dermatology and
medical products formulated with Invisicare. www.skinvisible.com
Forward-Looking Statements: This press release contains 'forward
looking' statements within the meaning of Section 21A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbors created thereby. Such statements
involve certain risks and uncertainties associated with an emerging company.
Actual results could differ materially from those projected in the forward
looking statements as a result of risk factors discussed in Skinvisible, Inc.
reports on file with the U.S. Securities and Exchange Commission (including,
but not limited to, a report on Form 10K for the quarter ending December 31,
Skinvisible Pharmaceuticals, Inc.
For further information:
For further information: Doreen McMorran of Skinvisible Pharmaceuticals,
Inc., +1-702-433-7154, email@example.com Web Site: